

RESPOND STUDY

PROVEN REAL-WORLD EFFECTIVENESS WITH PURAPLY® AM

The largest real-world effectiveness study
demonstrating that PuraPly AM supports healing
and aids in granulation tissue formation¹

THE STUDY

N=307
28 Sites

Prospective, multicenter
cohort study¹

Large
Difficult-to-Heal
Wounds

12.9 cm² mean wound area¹

THE RESULTS

86%

of wounds demonstrated
improvement in
wound bed conditions¹



Increased
granulation
tissue



Reduced
exudate



Readiness for
other advanced
skin substitutes

BASELINE DATA & WOUND TYPES TREATED¹

Mean patient age	70.3 years	Venous leg ulcers	67
Mean wound duration	96.2 days	Diabetic foot ulcers	62
Mean wound depth	5.2 mm	Pressure ulcers	45
Mean wound volume	11.2 cm ³	Post-surgical wounds	54
Mean # of applications*	5.2	Other wounds	79


*Patients received standard of care in addition to PuraPly AM over a 32-week study period

PURAPLY® AM SUPPORTED HEALING IN CHALLENGING WOUNDS

REDUCTION IN WOUND AREA, DEPTH, AND VOLUME

81%

of wounds achieved
> 60% reduction in area^{1,*}



*At 32 weeks


71%

of wounds achieved
> 60% reduction in depth^{1,*}



85%


of wounds achieved
> 75% reduction in volume^{1,*}



RATES OF WOUND CLOSURE


41.5%

of wounds achieved
complete closure at 12 weeks¹



17 WEEKS

Median time to closure
for all wounds¹



**Control bioburden, support healing, and aid in
granulation tissue formation with PuraPly AM¹⁻⁴**

Reference: 1. Bain MA, et al. *J Comp Eff Res*. 2020;9(10):691-703. 2. Davis SC, et al. *Int Wound J*. 2022;19(1):86-99. 3. Brantley J, et al. *Wounds Int*. 2016;7(3):1-5. 4. Data on file. PDR-0008. Organogenesis Inc.